Ionis Pharmaceutical (NASDAQ:IONS) has grabbed attention from the analysts, when it saw a value decrease of -3.94% or -2.73 points in the last trading session to close at $66.55. A total of 1.42 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 1.29 Million shares, while its relative volume stands at 1.1. Ionis Pharmaceutical (NASDAQ:IONS) has a market cap of $9.04 Billion and the number of outstanding shares have been calculated 135.89 Million.
Shares of Ionis Pharmaceutical (NASDAQ:IONS) currently have an Average Brokerage Recommendation of 2.91, number of Recs in ABR is 12 while industry rank of the company by ABR is out of 256. Out of the analyst recommendations 1 rate Ionis Pharmaceutical (NASDAQ:IONS) stock a Buy, 3 rate the stock Outperform, 9 rate Hold, 2 rate Underperform and 1 recommend a Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $69.5 on the stock, this valuation is based on 14 number of opinions. The most optimistic analyst sees the stock reaching $106 while the most conventional has $19 target price.
Ionis Pharmaceutical (NASDAQ:IONS) as of recent trade, has shown weekly downbeat performance of -8.51% which was maintained at -20.55% in 1-month period. During the past three months the stock gain 12.61%, bringing six months performance to 22.51%. Yearly performance of the stock shows a bullish trend of 55.49% while year-to-date (YTD) performance reflected 23.1% positive outlook.
While taking a glance at financials, we can look at a number of key indicators. Ionis Pharmaceutical (NASDAQ:IONS) has trailing twelve month Return on Assets of 14.4%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of 39.3% and a Return on Investment of 13.6%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Ionis Pharmaceutical (NASDAQ:IONS) has trailing twelve month gross margin at 51.8%, its trailing twelve month operating margin stands at 8.4% whereas its trailing twelve month net profit margin spots at 47.8%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0.76 whereas its trailing twelve month P/E ratio is 25.76. The company’s forward price to earnings ratio for next fiscal year is 169.34. Ionis Pharmaceutical (NASDAQ:IONS)’s price to free cash flow for trailing twelve months is 13.24. Its beta value stands at 2.32.
The company’s quick ratio for most recent quarter is 9.4 along with current ratio for most recent quarter of 9.4. Total debt to equity ratio of the company for most recent quarter is 0.55 whereas long term debt to equity ratio for most recent quarter is 0.54.